Docket No.: 105769-0007-104

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of Formula I, or a salt, solvate, or hydrate thereof:

$$R^1$$
 R^2
 R^3
 R^4

wherein

 R^1 and R^2 are each independently selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkyl CO_2 , NH₂, NH- C_{1-6} alkyl, N(C_{1-6} alkyl)(C_{1-6} alkyl), C_{1-6} alkyl(C=O)NH, C_{1-6} alkyl(C=O)N(C_{1-6} alkyl), SH, S- C_{1-6} alkyl, O-Si(C_{1-6} alkyl)(C_{1-6} alkyl)(C_{1-6} alkyl), NO₂, CF₃, OCF₃ and halo, or R^1 and R^2 together represent O- C_{1-6} alkyl-O, thereby forming a ring;

I

 R^3 is selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkyl CO_2 , NH₂, NH- C_{1-6} alkyl, N(C_{1-6} alkyl)(C_{1-6} alkyl), C_{1-6} alkyl(C=O)NH, C_{1-6} alkyl(C=O)N(C_{1-6} alkyl), SH, S- C_{1-6} alkyl, O-Si(C_{1-6} alkyl)(C_{1-6} alkyl), NO₂, halo and CH₂-S-(CH₂)_n Ar;

 R^4 is selected from $C(X)R^5$, SO_3Ar , NH_2 , $NH-C_{1-6}$ alkyl, $N(C_{1-6}$ alkyl)(C_{1-6} alkyl), $P(O)(OH)_2$, $P(O)(OC_{1-6}$ alkyl)₂, and $C(NH_2)=C(CN)_2$;

X is selected from O, S, NH and N-C₁₋₆alkyl;

 R^5 is selected from NH₂, OH, NH(CH₂)_pAr, NH(CH₂)_pOH, (CH₂)_pOC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkoxy, NHNH₂, NHC(O)NH₂, NHC(O)C₁₋₆alkoxy, N-morpholino and N-pyrrolidino; and

Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from OH, C₁₋₆alkyl, C₁₋₆alkyl, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, NO₂, CF₃, OCF₃ and halo;

n is 0 to 4; and

p is 1-4;

provided that at least one of R^1 , R^2 , and R^3 is selected from C_{1-6} alkyl CO_2 , C_{1-6} alkylC=ONH, or C_{1-6} alkylC=ON C_{1-

R¹ and R² together represent O-C₁₋₆alkyl-O, thereby forming a ring.

Amendment dated July 10, 2008 Reply to Office Action of April 23, 2008

2. (Withdrawn) The compound according to claim 1, wherein R^1 and R^2 are each independently selected from H, OH, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkyl CO_2 , NH₂, NH- C_{1-4} alkyl, C_{1-4} alkylC=0NH, C_{1-

- 3. (Withdrawn) The compound according to claim 2, wherein R¹ and R² are each independently selected from the group consisting H, OH, OCH₃, CH₃CO₂, O-Si(CH₃)₂(¹Bu), S-Me, SH, CH₃CONH, CH₃CONCH₃, and NO₂.
- 4. (Withdrawn) The compound according to claim 3, wherein R^1 and R^2 are both OH or R^1 and R^2 are both OCH₃.
- 5. (Withdrawn) The compound according to claim 4, wherein R¹ is OCH₃ and R² is OH.
- 6. (Original) The compound according to claim 1, wherein R³ is selected from H, OH, C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkylCO₂, NH₂, NH-C₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), C₁₋₄alkyl(C=O)NH, C₁₋₄alkyl(C=O)N(C₁₋₄alkyl), SH, S-C₁₋₄alkyl, NO₂ and halo.
- 7. (Currently Amended) The compound according to claim 6, wherein R³ is selected from H, OH, OCH₃, CH₃CO₂, SH, SMe, NO₂, CH₃CONH, CH₃CONCH₃, and halo.
- 8. (Withdrawn) The compound according to claim 1, wherein R^1 , R^2 , and R^3 are each independently selected from H, C_{1-4} alkyl CO_2 , C_{1-6} alkyl(C=O)NH, and C_{1-6} alkyl $(C=O)N(C_{1-6}$ alkyl), provided that at least one of R^1 , R^2 , and R^3 is not hydrogen.
- 9. (Currently Amended) The compound according to claim 1, wherein R^4 is selected from $C(X)R^5$ and $C(NH_2)=C(CN)_2$.
 - 10. (Original) The compound according to claim 9, wherein R^4 is $C(X)R^5$.

Docket No.: 105769-0007-104

11. (Currently Amended) The compound according to claim 10, wherein X is selected fromselected-from O and S.

- (Currently Amended) The compound according to claim 10, wherein R⁵ is selected 12. from selected from NH₂, OH, NH(CH₂)_pAr, NH(CH₂)_pOH and C₁₋₄alkoxy.
 - (Original) The compound according to claim 12, wherein p is 1-3. 13.
- (Currently Amended) The compound according to claim 13, wherein R⁵ is selected 14. from selected from NH₂, OH, NH(CH₂)_pAr, NH(CH₂)_pOH and OCH₃.
 - 15. (Original) The compound according to clam 14, wherein p is 1-2.
- 16. (Currently Amended) The compound according to claim 1, wherein Ar is an unsubstituted phenyl group or a phenyl group substituted with 1-4 substituents optionally selected from Selected from OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl), CH₁₋₆alkyl), SH, S-C₁₋₆alkyl, N(C₁₋₆alkyl), N(C₁ 6alkyl, NO₂, CF₃, OCF₃ and halo.
- 17. (Currently Amended) The compound according to claim 14, wherein Ar is an unsubstituted phenyl group or a phenyl group substituted with 1-4 substituents optionally selected from Selected from OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, N(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, SH, S-C₁₋₆alkyl, N(C₁₋₆alkyl), N(C₁₋₆alkyl), N(C₁₋₆alkyl), N(C 6alkyl, NO₂, CF₃, OCF₃ and halo.
- 18. (Currently Amended) The compound according to any of claims 16 and 17, wherein Ar is an unsubstituted phenyl group or phenyl group substituted with 1-2 substituents optionally selected from OH, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, NH-C₁₋₄alkyl, N(C₁₋₄alkyl), (C₁₋₄alkyl), SH, S-C₁₄alkyl, NO₂, CF₃, OCF₃ and halo.

Application No. 10/593,851 Docket No.: 105769-0007-104 Amendment dated July 10, 2008

Reply to Office Action of April 23, 2008

19. (Original) The compound according to claim 18, wherein Ar is an unsubstituted phenyl group or phenyl group substituted with 1-2 substituents optionally selected from OH, OCH₃, NH₂, NHCH₃, N(CH₃)₂, SH, SCH₃, CF₃, OCF₃ and halo.

20. (Currently Amended) A compound selected from:

Amendment dated July 10, 2008 Reply to Office Action of April 23, 2008

Docket No.: 105769-0007-104

Н

ĊΝ

÷

MeO

HO

ĊN

Docket No.: 105769-0007-104

HO

ÒМе

Application No. 10/593,851 Amendment dated July 10, 2008

Reply to Office Action of April 23, 2008

÷

MeO OMe MeO НО ÒМе ÷ Me MeO Ме H ĊΝ HO ÒМе ÷ MeO H ĆΝ НО ÓМе ÷ СООН MeO НО ÒМе OMe MeO ĊN HO ОМе ÒМе ÷ MeO ĊN HO ОМе ÓМе ÷ MeO ĊN HO ÓМе ÷ ОМе MeO OMe ĊN HO

÷

ÓМе

Docket No.: 105769-0007-104

Application No. 10/593,851 Amendment dated July 10, 2008 Reply to Office Action of April 23, 2008

÷

÷

ÓМе

ŌН OH. ĊΝ Me÷ ĊΝ Me MeO 0 H ĊN OMe H ĊΝ ÷ ĆΝ Н ĊΝ ĊN

ĊΝ

22

Docket No.: 105769-0007-104

Application No. 10/593,851 Amendment dated July 10, 2008

Reply to Office Action of April 23, 2008

Application No. 10/593,851 Docket No.: 105769-0007-104 Amendment dated July 10, 2008

Reply to Office Action of April 23, 2008

Docket No.: 105769-0007-104

Application No. 10/593,851 Docket No.: 105769-0007-104 Amendment dated July 10, 2008

Reply to Office Action of April 23, 2008

21. (Currently Amended) A composition comprising a compound according to any one of-claims 1 to 20 in admixture with a pharmaceutically acceptable diluent or carrier.

22-29. (Cancelled).

- 30. (Withdrawn, Currently Amended) A method of modulating cell proliferation comprising administering an effective amount of a compound capable of modulating cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.
- 31. (Withdrawn, Currently Amended) A method of inhibiting cell proliferation comprising administering an effective amount of a compound capable of inhibiting cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.

Application No. 10/593,851 Amendment dated July 10, 2008

Reply to Office Action of April 23, 2008

(Withdrawn, Currently Amended) A method of inhibiting cancer cell proliferation 32. comprising administering an effective amount of a compound capable of inhibiting cancer cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.

- 33. (Withdrawn, Currently Amended) A method of treating cancer comprising administering an effective amount of a compound capable of inhibiting cancer cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.
- 34. (Withdrawn) A method according to claim 32 or 33 wherein said cancer is a hematopoietic cell cancer.
- 35. (Withdrawn) A method according to claim 32 or 33 wherein said cancer is a leukemia, a lymphoma, a myeloma or a carcinoma.
- 36. (Withdrawn) A method according to claim 35 wherein said leukemia is acute lymphoblastic leukemia, aggressive Philadelphia+ leukemia, acute myelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia or juvenile myelomonocyte leukemia,
- 37. (Withdrawn) A method according to claim 35 wherein said leukemia is acute lymphoblastic leukemia.